ASP Isotopes issued a shareholder letter ahead of its second quarter 2026 financial results, highlighting strong operational progress and providing revenue forecasts for key divisions. The company noted significant growth in its PET Labs unit and key milestones for its Renergen and stable isotope projects.
Key Highlights
- The PET Labs division's organic revenue grew over 50% in the first half of 2026 compared to the same period last year, with full-year 2026 revenue forecasted at approximately $14 million.
- Helium production at the Renergen facility is expected to commence before September 30, 2026, with annualized revenue projected at approximately $27 million after Phase 1 is complete.
- The company expects initial commercial shipments of enriched Silicon-28 and Ytterbium-176 in the second half of 2026, following delays related to supplier equipment.